Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study

[1]  E. Ganse,et al.  Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up , 2017, Osteoporosis International.

[2]  J. Kenkre.  Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? , 2015, Annals of clinical biochemistry.

[3]  S. Cummings,et al.  Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. , 2014, JAMA internal medicine.

[4]  A. Bower,et al.  Patterns of treatment among a cohort of older low-income adults starting new medications for osteoporosis , 2014, Osteoporosis International.

[5]  P. Muntner,et al.  Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries , 2014, BMC Musculoskeletal Disorders.

[6]  C. Roux,et al.  How long should we treat? , 2014, Osteoporosis International.

[7]  D. Matlock,et al.  "Due" for a scan: examining the utility of monitoring densitometry. , 2013, JAMA internal medicine.

[8]  A. Schott,et al.  Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. , 2012, European journal of endocrinology.

[9]  O. Ström,et al.  Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA) , 2012, Osteoporosis International.

[10]  P. Geusens,et al.  Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands , 2010, Osteoporosis International.

[11]  S. Cummings,et al.  Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  A. Tosteson,et al.  Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™ , 2010, Osteoporosis International.

[13]  J. Eisman,et al.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.

[14]  K. Safranow,et al.  Common drug switching during long-term antiresorptive treatment: experience of four osteoporosis centers in Poland (2001–2005) , 2008, Aging clinical and experimental research.

[15]  J. Fernandes,et al.  Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  J. Avorn,et al.  Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. , 2007, The American journal of medicine.

[17]  E. Platz,et al.  Prevalence and risk factors for erectile dysfunction in the US. , 2007, The American journal of medicine.

[18]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[19]  S. Giannini,et al.  Determinants of adherence to osteoporosis treatment in clinical practice , 2006, Osteoporosis International.

[20]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[21]  David B. Nash,et al.  Clinical Vignette-Based Surveys: A Tool for Assessing Physician Practice Variation , 2005, American journal of medical quality : the official journal of the American College of Medical Quality.

[22]  Jeff Luck,et al.  Measuring the Quality of Physician Practice by Using Clinical Vignettes: A Prospective Validation Study , 2004, Annals of Internal Medicine.

[23]  R. Marcus.  Post-menopausal osteoporosis. , 2002, Best practice & research. Clinical obstetrics & gynaecology.

[24]  J W Peabody,et al.  Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. , 2000, JAMA.

[25]  H K Genant,et al.  Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. , 1999, Archives of internal medicine.

[26]  J. Françon.  [Post-menopausal osteoporosis]. , 1953, Rhumatologie.

[27]  Jacques P. Brown,et al.  Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[28]  M. Laporte.  [Treatment of osteoporosis]. , 1970, Bordeaux medical.